Clinical Trial Update: Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating anti-HIV immunoglobulin (HIVIG) for prevention of maternal-fetal HIV transmission has completed. The Pediatric ACTG Protocol 185 study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• HIV Infection

Drugs mentioned

• HIV Immunoglobulin (HIVIG) (HIV immunoglobulin)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Acquired Immunodeficiency Syndrome, Disease Transmission, Vertical | Phase 3 | Status: COMPLETED